Precision Optics Schedules Second Quarter of Fiscal Year 2026 Conference Call for February 17, 2026
MWN-AI** Summary
Precision Optics Corporation, Inc. (Nasdaq: POCI), a prominent designer and manufacturer specializing in advanced optical instruments for the medical and defense/aerospace sectors, has announced the scheduling of its second quarter fiscal year 2026 conference call. The call will take place on February 17, 2026, at 5:00 p.m. ET, following the release of the Company’s financial results and the filing of its 10-Q document, which will occur after the market closes on the same day.
For those interested in participating, the conference call can be accessed by dialing (844) 735-3662 or (412) 317-5705. Additionally, a live webcast will be available at https://app.webinar.net/Zo5aLdzPzmg. A replay of the call will be offered for seven days through a teleconference or via the same webcast link used for the live event.
Precision Optics has been operational since 1982 and is known for its expertise in micro-optics, 3D imaging, and digital imaging technologies, catering primarily to the healthcare and defense/aerospace industries. The Company’s offerings extend from product concept development to mass manufacturing, showcasing its in-house design, prototype, regulatory, and fabrication capabilities. Precision Optics’s innovations have enabled advancements in minimally invasive surgical devices and the rapid adoption of robotic surgical systems, along with providing a range of critical optical products to leading medical device manufacturers.
The press release also contains forward-looking statements reflecting the Company's expectations regarding future performance, based on management’s evaluations and assumptions. However, these projections involve inherent risks and uncertainties that may lead to actual outcomes differing from what has been anticipated.
For further details, stakeholders are encouraged to visit the Company’s website or contact investor relations directly.
MWN-AI** Analysis
As Precision Optics Corporation (Nasdaq: POCI) prepares for its second quarter fiscal results release on February 17, 2026, investors should approach this announcement with a mix of optimism and caution. The company’s dual focus on advanced optical instruments for the medical and defense/aerospace industries positions it strategically within high-demand sectors, particularly as they continue to grow in response to technological advancements and increasing regulatory requirements.
Investors should analyze key metrics from the upcoming earnings report, particularly revenue growth, margins, and order backlog. Given the structural shift towards minimally invasive surgical procedures and advanced imaging technologies, a significant uptick in orders from medical device firms could bolster results. Conversely, any supply chain disruptions—already a widespread concern across the manufacturing landscape—could negatively impact production capabilities, thereby affecting revenue projections.
The company's considerable investments in proprietary technologies like micro-optics and 3D imaging have established a competitive edge. However, scrutiny over cost management and operational efficiencies will be essential, especially if margins face pressure due to rising input costs or increased competition.
Market sentiment may also play a critical role following the earnings call. Pay close attention to management’s forward-looking statements, which could provide insight into growth prospects and potential challenges. Given the recent volatility in equity markets, stock performance may also be amplified by market reactions to both the reported numbers and any guidance provided.
In summary, while Precision Optics boasts a robust business model with substantial growth potential, investors should remain wary of external market pressures and demand fluctuations. Monitoring the Q2 earnings call—and the context around any guidance—will be vital for making informed investment decisions moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
GARDNER, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company’s second quarter fiscal year 2026 financial results on Tuesday, February 17, 2026, at 5:00 p.m. ET.
The Company intends to release its financial results and to file its 10-Q after the close of the market on Tuesday, February 17, 2026, followed by the conference call.
Conference Call Details
Date and Time: Tuesday, February 17, 2026, at 5:00 p.m. ET.
Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or
(412) 317-5705.
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/Zo5aLdzPzmg.
Replay: A teleconference replay of the call will be available for seven days, at (855) 669-9658 or (412) 317-0088, replay access code 3100136. A webcast replay will be available at https://app.webinar.net/Zo5aLdzPzmg.
About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.
About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company's products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company's filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
Company Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800
Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
poci@lythampartners.com
FAQ**
What key financial metrics do you expect Precision Optics Corporation Inc. POCI to report for Q2 of fiscal year 2026, and how do they compare to previous quarters?
Can you provide insight into the future demand trends for Precision Optics Corporation Inc. POCI's products in the healthcare and defense/aerospace sectors?
How is Precision Optics Corporation Inc. POCI addressing current global supply chain challenges that may impact its operations and product delivery?
What forward-looking strategies does Precision Optics Corporation Inc. POCI plan to implement to sustain growth and innovation in next-gen optical technologies?
**MWN-AI FAQ is based on asking OpenAI questions about Precision Optics Corporation Inc. (NASDAQ: POCI).
NASDAQ: POCI
POCI Trading
1.7% G/L:
$4.37 Last:
15,882 Volume:
$4.41 Open:
